

Suja S. Rajan, M.H.A., M.S., Ph.D.

CURRENT APPOINTMENT AND ADDRESS

Associate Professor (September, 2016 – Current)
Department of Management, Policy and Community Health
University of Texas (UT) – School of Public Health (SPH)
E-319, 1200 Pressler Street, Houston, TX 77030
Tel (713) 500-9194; Fax (713) 500-9171
Email: suja.s.rajan@uth.tmc.edu

Secondary Appointment, Department of Biostatistics, UT SPH (July 2015 – present)

CENTER AFFILIATIONS

Center for Health Services Research, UT SPH, 2012-present
Center for Management and Policy in Population Health, UT SPH, 2012-present

A. BACKGROUND

A.1 EDUCATION

- 2001: Bachelor of Science – B. S. (Specialization - Clinical/Cardiac Sciences), **Birla Institute of Technology and Science** – BITS (Ranked among the top 5 universities for Engineering and Science in India), Chennai, India
- 2003: Master of Health Administration (M.H.A.), **The Ohio State University** (OSU), Columbus, OH
- 2007: Master of Science (M.S.), Economics, **University of North Carolina** (UNC), Chapel Hill, NC
- 2009: Ph.D. Health Policy and Management (Specialization in Health Economics), **UNC**, Chapel Hill, NC

A.2 HONORS AND AWARDS

- 2014 Annual Research Award – UT SPH – David R. Lairson (mentor) and Suja S. Rajan (mentee) (\$1,000 cash award each)
- 2011 Best poster – 16th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Baltimore, Maryland
- 2010 Best poster - 11th Annual Health Services and Outcomes Research Conference, Kelsey Research Foundation, Houston, Texas
- 2009 Best poster - 10th Annual Health Services and Outcomes Research Conference, Kelsey Research Foundation, Houston, Texas
- 2005 Family Health International Fellowship – UNC SPH (PhD)
- 2004 Chancellor's List for graduate students – UNC (PhD); UNC Graduate School does not assign grades or GPA
- 2003 Faculty Award for Academic Excellence (**GPA: 3.96/4**) – OSU SPH (MHA)
- 2003 Phi Kappa Phi honor for exemplary performance in the University – OSU (MHA)
- 2001 University Fellowship – OSU (MHA)
- 2001 Gold Medal for best academic performance (**GPA: 10/10**) – BS class of 2001, BITS
- 1997 Merit Certificate for best performance in Chemistry (High School)
- 1995 National Merit Scholarship – Top 0.1% performers in the nation for Social Sciences (High School)

A.3 PROFESSIONAL EXPERIENCE

- 9/2016 – Present Associate Professor, Department of Management, Policy and Community Health, UT SPH
Secondary Appointment – Biostatistics, UT SPH (7/2015 – present)
- 2/2012 – 8/2016 Assistant Professor, Department of Management, Policy and Community Health, UT SPH

7/2009 – 1/2012	Assistant Professor, University of Houston – College of Pharmacy, Houston, TX
5/2007 – 5/2008	SEER-Medicare Coordinator – The Cecil G. Sheps Center for Health Services Research UNC, Chapel Hill, NC
9/2005 – 8/2007	Research Fellow – collaborating with Dr. David Sokal Family Health International, Durham, NC
5/2005 – 8/2005	Summer Intern - collaborating with Dr. Frank Sloan and Dr. Tom Hoerger Research Triangle Institute, Research Triangle Park, NC
5/2004 – 8/2004	Summer Intern – collaborating with Dr. Felicia Mebane UNC, Chapel Hill, NC
8/2003-5/2005	Research Assistant - under Dr. George Pink UNC, Chapel Hill, NC
6/2002-9/2002	Summer Administrative Intern University Hospitals, OSU, Columbus, OH
8/2000-6/2001	Student Intern Department of Cardiac Surgery, Madras Medical Mission, Chennai, India

B. RESEARCH

B.1.1 GRANTS - PRINCIPAL INVESTIGATOR

1. Role: Principal Investigator (Effort: 20%)
Sponsor: **National Institute of Health - National Cancer Institute (1R03CA181977-01)**
Title: “Effectiveness of Pegfilgrastim vs Filgrastim in Elderly Breast Cancer Patients”
Duration: 01/01/2014-12/31/2016 (Completed)
Amount: \$150,000
2. Role: Principal Investigator
Sponsor: **PRIME award – UT SPH**
Title: “Impact of Breast Cancer Stage at Diagnosis on Long-term Adverse Events of G-CSF”
Duration: 05/01/2012-04/30/2013 (Completed)
Amount: \$25,000
Note: Some results from this were used as preliminary analysis for the NIH-NCI grant application above
3. Role: Principal Investigator
Sponsor: **New Faculty Research Award – University of Houston**
Title: “Primary Prophylaxis of Neutropenia Using Pegfilgrastim versus Filgrastim in Real-Life Clinical Settings for Elderly Breast Cancer Patients Receiving Chemotherapy”
Duration: 02/01/2010-08/31/2010 (Completed)
Amount: \$6,000

B.1.2 GRANTS - PRINCIPAL INVESTIGATOR (PI) FOR SUB-CONTRACT

4. Role: Sub-contract PI (Effort: 10%) PI: Salim Virani
Sponsor: **American Diabetes Association Clinical Science and Epidemiology Award**
Title: “Comparative Effectiveness of Physicians versus Non-physicians for the Delivery of Outpatient Diabetes Care: Implications for Access to Care under the Affordable Care Act”

- Duration 01/01/2016-12/31/2017
Amount: \$173,913
5. Role: Sub-contract PI (Effort: 5%) PI: Laura Petersen
Sponsor: **Houston Veterans Affairs Health Services Research & Development Center of Excellence**
Title: "Improving the Measurement of VA Facility Performance to Foster a Learning Healthcare System"
Duration 01/01/2017-12/31/2019
Amount: \$1,097,800
6. Role: Sub-contract PI (Effort: 20%) PI: Laura Petersen
Sponsor: **Houston Veterans Affairs Health Services Research & Development Center of Excellence**
Title: "Peer Facilities – Veterans Integrated Service Networks Contract"
Duration 04/01/2014-12/31/2016 (Completed)
Amount: \$410,479

B.1.3 GRANTS – CO-INVESTIGATOR

7. Role: Co-Investigator (Effort: 20%) PI: James Grotta
Sponsor: **Patient-Centered Outcomes Research Institute**
Title: "BENEFITS OF STROKE TREATMENT DELIVERED USING A MOBILE STROKE UNIT COMPARED TO STANDARD MANAGEMENT BY EMERGENCY MEDICAL SERVICES: THE BEST-MSU STUDY"
Duration 09/01/2016-08/31/2021
Amount: \$2,201,419 (this is only SPH's share)
8. Role: Co-Investigator (Effort: 20%) PI: Linda Highfield
Sponsor: **Agency for Healthcare Research and Quality**
Title: "Evidence Based Dissemination for Mammography Adherence in Safety Net Communities"
Duration 07/01/2014-12/31/2017
Amount: \$1,493,000
9. Role: Co-Investigator (Effort: 20%) PI: James Grotta
Sponsor: **Halle Center**
Title: "Benefits of Stroke Treatment Delivered Using a Mobile Stroke Unit: The BEST-MSU Study"
Duration 09/01/2014-04/30/2017 (Completed)
Amount: \$1,897,315 (this is only SPH's share)
10. Role: Co-investigator (Effort: 20%); PI: Frances Lee Revere
Sponsor: **Center for Medicare & Medicaid Services - Texas Department of Insurance**
Title: "Texas Proposal to Establish a Data Center"
Duration 10/01/2013-09/30/2014 followed by 10/01/2015-09/30/2016 (Completed)
Amount: \$2,078,000
11. Role: Co-investigator (Effort: 5%) PI: Charles E. Begley and Frances Lee Revere
Sponsor: **Methodist Healthcare Ministries/Association of Community-Based Health Plans**
Title: "Medicaid and Commercial MarketScan Comparative Study"
Duration 08/01/2015-10/31/2016 (Completed)
Amount: \$99,724
12. Role: Co-investigator (Effort: 5%) PI: Paul Rowan
Sponsor: **The Meadows Foundation, Inc.**
Title: "Serious and Persistent Mental Illness in Medicaid: Descriptive Analysis and Policy Options for Texas"
Duration 06/01/2015-05/31/2016 (Completed)

- Amount: \$50,000
13. Role: Co-investigator (Effort: 10%) PI: Barbara Tilley
 Sponsor: **National Institute of Health (2U01NS043127-12)**
 Title: Parkinson's Disease Clinical Trial
 Duration: 12/01/2013 - 11/30/2015 (Completed)
 Amount: \$2,966,235
14. Role: Co-investigator (Effort: 5%) PI: Paul Rowan
 Sponsor: **The Meadows Foundation, Inc.**
 Title: "Serious and Persistent Mental Illness in Medicaid: Descriptive Analysis and Policy Options for Texas"
 Duration: 02/01/2014-01/31/2015 (Completed)
 Amount: \$99,817
15. Role: Co-investigator (Effort: 20%) PI: Frances Lee Revere and Charles E. Begley
 Sponsor: **Methodist Healthcare Ministries/Association of Community-Based Health Plans**
 Title: "Medicaid and Blue Cross Blue Shield Comparative Study"
 Duration: 01/01/2014-12/31/2014 (Completed)
 Amount: \$109,000
16. Role: Co-investigator (Effort: 10%) PI: Charles E. Begley
 Sponsor: **Cancer Prevention and Research Institute of Texas**
 Title: "Texas Breast Cancer Early Detection and Treatment Program Outcomes Study"
 Duration: 08/01/2010-07/31/2012 (Completed)
 Amount: \$146,070

B.1.4 GRANTS SUBMITTED – PENDING OR NOT FUNDED (Only ones submitted at UTSPH starting fall 2012)

1. Active Implementation of an Evidence-Based CRC Screening Intervention in a Health System
Submitted: October 2017 (first submitted)
 Proposed Start/End Date: 07/01/2018-06/30/2023
 Funding Agency: NIH
 Role: Co-Investigator
Project Status: Submitted
2. Health Services Research Training Program at UTHealth
Submitted: September 2017 (first submitted)
 Proposed Start/End Date: 07/01/2018-06/30/2023
 Funding Agency: AHRQ (T32)
 Role: Mentor
Project Status: Submitted
 Total Direct Costs: \$1,809,890
 Total Indirect Costs: \$134,770
3. Dissemination and Implementation of Evidence Based Approaches to Promote Mammography Adherence in Safety Net Communities
Submitted: August 2017 (first submitted)
 Proposed Start/End Date: 04/01/2018 - 03/31/2023
 Funding Agency: NIH
 Role: Co-Investigator
Project Status: Submitted
 Total Direct Costs: \$2,481,653
 Total Indirect Costs: \$776,243

4. Implementation and Sustainability of the Empowering Patients in Chronic Care Diabetes Program
Submitted: July 2017 (first submitted)
Proposed Start/End Date: 10/01/2017-09/31/2019
Funding Agency: Health Services Research and Development, Veterans Health Administration
Role: Co-Investigator
Project Status: Not funded
Total Direct Costs: \$ 300,000
Total Indirect Costs: no indirect allowed

5. Letter of intent (June 2017) and subsequent grant (August 2017) submitted to the **Texas Medical Center - Health Policy Institute** – “Value-over-volume in breast cancer care: The role of small area and provider-level variations in Texas”. (Role: Principal Investigator).

6. Comparative and Cost Effectiveness of Reperfusion Therapies for Acute Ischemic Stroke
Submitted: June 2017 (first submitted)
Proposed Start/End Date: 11/01/2017-01/31/2019
Funding Agency: Genentech
Role: Co-Principal Investigator
Project Status: Submitted
Total Direct Costs: \$190,415
Total Indirect Costs: \$57,125

7. Hybrid Type III effectiveness-implementation trial of provider support strategies to facilitate delivery of evidence based psychotherapy for depression in primary care mental health clinics
Submitted: June 2017 (first submitted)
Proposed Start/End Date: 01/01/2018-12/31/2021
Funding Agency: Health Services Research and Development, Veterans Health Administration
Role: Co-Investigator
Project Status: Not Funded
Total Direct Costs: \$1,094,944
Total Indirect Costs: no indirect allowed

8. The Safer Dx Learning Lab: A Demonstration Project For Improving Diagnostic Safety
Submitted: May 2017 (first submitted)
Proposed Start/End Date: 07/01/2017-06/30/2020
Funding Agency: Gordon and Betty Moore Foundation
Role: Health Economist/Co-Investigator
Project Status: Funded
Total Direct Costs: \$3,307,211
Total Indirect Costs: \$218,186

9. Cancer Prevention and Control Research Training and Career Development Program
Submitted: May 2017 (first submitted)
Proposed Start/End Date: 09/01/2018 - 08/31/2023
Funding Agency: NIH-NCI
Role: Mentor
Project Status: Submitted
Total Direct Costs: \$1,855,766.00
Total Indirect Costs: \$138,030.003

10. Using a Learning Community Approach to Increase Colorectal Cancer Screening and Reduce Disparities in Health Systems
Submitted: February 2017 (first submitted)

Proposed Start/End Date: 12/01/2017 - 11/30/2022

Funding Agency: NIH / NCI

Role: Co-Investigator

Project Status: Not Funded

Total Direct Costs: \$117,020

Total Indirect Costs: \$63,194

11. Letter of intent (Summer 2016) and subsequent grant (September 2016) submitted to the **Texas Medical Center - Health Policy Institute** – “The Effect of Advanced Chronic Kidney Disease Care on Employment following Kidney Failure in Texas”. (Role: Co-Investigator).

12. Casual models to evaluate periodontal treatment effects on cardiovascular disease
Submitted: June 2016 (first submitted)/Resubmitted June 2017
Proposed Start/End Date: 01/01/2018 - 12/31/2020
Funding Agency: Health Services Research and Development, Veterans Health Administration
Role: Co-Investigator
Project Status: Re-submitted
Total Direct Costs: \$1,100,000 (Approximate)
Total Indirect Costs: no indirect allowed

13. Strengthening primary care-senior center linkages to improve diabetes outcomes
Submitted: July 2016 (first submitted)
Proposed Start/End Date: 01/01/2017 - 12/31/2021
Funding Agency: NIH / NIDDK
Role: Co-Investigator
Project Status: Not Funded
Total Direct Costs: \$222,255
Total Indirect Costs: \$120,017

14. Benefits of Stroke Treatment Delivered Using a Mobile Stroke Unit Compared to Standard Management by Emergency Medical Services: The BEST-MSU Study - Data Coordinating Center (U01 NINDS Phase III Investigator-Initiated Efficacy Clinical Trial)
Submitted: June 2016 (first submitted)
Proposed Start/End Date: 04/01/2017 - 03/31/2022
Funding Agency: NIH / NINDS
Role: Co-Investigator
Project Status: Not Funded
Total Direct Costs: \$2,095,985
Total Indirect Costs: \$1,098,083

15. Benefits of Stroke Treatment Delivered Using a Mobile Stroke Unit Compared to Standard Management by Emergency Medical Services: The BEST-MSU Study
Submitted: February 2016 (first submitted)
Proposed Start/End Date: 10/01/2016-09/30/2021
Funding Agency: PCORI
Role: Co-Investigator
Project Status: Funded
Total Direct Costs: \$1,572,724
Total Indirect Costs: \$629,089

16. Three letters of intent and two subsequent grant proposals to the **Texas Medical Center - Health Policy Institute** in FY 2015 (One as principal investigator and two as co-investigator). All three got invited to re-submit but we withdrew one application due to conflicts with the timeline. The other two completed grant applications were submitted FY 2016/December 2015. The titles of the three letters of intent/grant proposals were:

- a. Houston Mobile Stroke Unit Economic Evaluation Project (PI) - Withdrawn
 - b. Comparative study of Birth Outcomes in Texas Medicaid and Private Insurance enrolled women (Co-I)
 - c. Texas PPACA Health Insurance Exchange Participation: Are There Positive Spillovers for Medicaid Recipients? (Co-I)
17. Less is More: Improving antimicrobial stewardship for asymptomatic bacteriuria
Submitted: December 2015 (first submitted) / Resubmitted May 2016
Proposed Start/End Dates: 01/01/2017-12/31/2019
Funding Agency: Health Services Research and Development, Veterans Health Administration
Role: Co-Investigator
Project Status: Funded
Total direct costs: \$1,099,000
Total Indirect Costs: no indirect allowed
 18. Improving the Measurement of VA Facility Performance to Foster a Learning Healthcare System
Submitted: June 2015 (first submitted) / Resubmitted December 2015/ Resubmitted May 2016
Proposed Start/End Date: 01/01/2017-12/31/2019
Funding Agency: Health Services Research and Development, Veterans Health Administration
Role: Co-Investigator
Project Status: Funded
Total Direct Costs: \$ 1,097,800
Total Indirect Costs: no indirect allowed
 19. Implementing the B-TIME Approach for Evidence Based Stroke Swallowing Screening
Submitted: June 2015 (first submitted) / Resubmitted December 2015
Proposed Start/End Date: 07/01/2016-06/30/2020
Funding Agency: Health Services Research and Development, Veterans Health Administration
Role: Co-Investigator
Project Status: Not Funded
Total Direct Costs: \$1,100,000 (Approximate)
Total Indirect Costs: no indirect allowed
 20. Benefits of Stroke Treatment Delivered Using a Mobile Stroke Unit Compared to Standard Management by Emergency Medical Services: The BEST-MSU Project
Submitted: June 2014 (first submitted) and March 2015 (re-submitted)
Proposed Start/End Date: 10/01/2014 - 09/30/2019
Funding Agency: NIH / NHLBI
Role: Co-Investigator
Project Status: Not Funded
Total Direct Costs: \$1,220,918
Total Indirect Costs: \$618,629
 21. Multi-component interventions for patients and providers to increase HPV vaccination in a network of pediatric clinics in Houston
Submitted: July 2014 (first submitted)
Proposed Start/End Date: 03/01/2015 - 02/28/2018
Funding Agency: Cancer Prevention and Research Institute of Texas
Role: Co-Investigator
Project Status: Submitted/Funded (Requested mentor and colleague Dr. David R. Lairson to take over this grant due to the timing of grant initiation during my maternity leave)
Total Direct Costs: \$1,451,013
Total Indirect Costs: \$76,366

22. Applying a B-TIME Approach to Implement Evidence Based Stroke Dysphagia Screening

Submitted: December 2013 (first submitted)

Proposed Start/End Date: 04/01/2015-03/31/2019

Funding Agency: Veterans Health Administration/ Quality Enhancement Research Initiative

Role: Co-Investigator

Project Status: Awarded – But the project was eventually not funded because the funding agency lost money

Total Direct Costs: \$263,751 (Total for three personnel from UT SPH/MPACH)

Total Indirect Costs: no indirect allowed

23. Incorporating Efficiency Into Cholesterol Performance Measurement

Submitted: December 2013 (first submitted)

Proposed Start Date: 04/01/2015-03/31/2019

Funding Agency: Veterans Health Administration

Role: Co-Investigator

Project Status: Not Funded

Total Direct Costs: \$80,255

Total Indirect Costs: no indirect allowed

24. Effect of Body Mass Index on Initial Treatment Phase Cost of Breast Cancer

Submitted: June 2013 (first submitted)

Proposed Start/End Date: 09/01/2013 - 08/31/2014

Funding Agency: Kaiser Foundation / NIH / NCI

Role: Principal Investigator

Project Status: **Not Funded**

Total Direct Costs: \$ 47,763

Total Indirect Costs: \$ 27,218

25. UT Houston Infrastructure Development in Patient-Centered Outcomes Research

Submitted: December 2012 (first submitted)

Proposed Start/End Date: 09/01/2013 - 08/31/2018

Funding Agency: Agency for Healthcare Research and Quality

Role: Scholar/Co-Investigator (to be covered 25% per year for 5 years)

Project Status: **Not Funded**

Total Direct Cost: \$3,278,938

Total Indirect Cost: \$1,705,049

26. Cancer Research Network Scholars Program

Submitted: December 2012 (first submitted)

Proposed Start/End Date: 03/01/2013 - 05/31/2015

Funding Agency: Cancer Research Network / NIH / NCI

Role: Principal Investigator

Project Status: **Not Funded**

Total Direct Cost: 10% of Salary for 2 years

Total Indirect Cost: no indirect allowed

27. Comparative Effectiveness of Pharmacotherapy in Pediatric Bipolar Disorder

Submitted: October 2012 (first submitted)

Proposed start/End Date: 04/01/2013-03/31/2015

Funding Agency: NIH/NIMH

Role: Consultant for Health Economics

Project Status: Not Funded

Total Direct Cost: \$5,000 (Grant Total: \$150,000)

Total Indirect Cost: NA

B.2.1 PEER-REVIEWED JOURNAL PUBLICATIONS

**** Students primarily mentored by Suja S. Rajan (which involved complete supervision of analysis and extensive writing of the manuscript)**

*** Other student authors for whom Suja S. Rajan was not the primary mentor**

‡ Suja S. Rajan is the Corresponding author

† Publications from funded grants

1. Virani SS, Akeroyd JM, Ramsey DJ, Deswal A, Nasir K, **Rajan SS**, Ballantyne CM, Petersen LA. Healthcare Resource Utilization for Outpatient Cardiovascular Disease and Diabetes Care Delivery among Advanced Practice Providers and Physician Providers in Primary Care. Accepted August 2017.
2. Bhise V**, **Rajan SS**, Sittig DF, Morgan RO, Chaudhary P, Singh H. Defining and Measuring Diagnostic Uncertainty in Medicine: A Systematic Review. *J Gen Intern Med*. Epub 2017 Sep 21. PMID: 28936618
3. Taylor JS, **Rajan SS**, Zhang N, Meyer LA, Ramondetta LM, Bodurka DC, Lairson DR, Giordano SH. End-of-Life Racial and Ethnic Disparities Among Patients With Ovarian Cancer. *J Clin Oncol*. 2017 Jun 1;35(16):1829-1835. PMID: 28388292 PMCID: PMC5455594
4. **Rajan SS**‡, Suryavanshi MS, Karanth S, Lairson DR. The Immediate Impact of the 2009 USPSTF Screening Guideline Change on Physician Recommendation of a Screening Mammogram: Findings from a National Ambulatory and Medical Care Survey-Based Study. *Popul Health Manag*. 2017 Apr;20(2):155-164. PMID: 27564582
5. **Rajan SS**, Cai Y, Yi M, Tsai CL, Du XL. Use of Hematopoietic Growth Factors in Elderly Lung Cancer Patients Receiving Chemotherapy: A SEER-Medicare Based Study. *Am J Clin Oncol*. 2017 Feb;40(1):66-74. PMID: 25068470
6. Yamal JM†, **Rajan SS**, Parker SA, Jacob AP, Gonzalez MO, Gonzales NR, Bowry R, Barreto AD, Wu TC, Lairson DR, Persse D, Tilley BC, Chiu D, Suarez JI, Jones WJ, Alexandrov A, Grotta JC. Benefits of Stroke Treatment Delivered Using a Mobile Stroke Unit Trial. *Int J Stroke*. Epub 2017 Jan. PMID: 28612680
7. Cao Y*, **Rajan SS**, Wei P. Mendelian Randomization Analysis of a Time-varying Exposure for Binary Disease Outcomes using Functional Data Analysis Methods. *Genetic Epidemiology*. 2016 Dec;40(8):744-755. PMID: 27813215 PMCID: PMC5123677
8. Virani SS†, Akeroyd JM, Ramsey DJ, Chan WJ, Frazier L, Nasir K, **Rajan SS**, Ballantyne CM, Petersen LA. Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care Act. *American Heart Journal*. 2016 Nov;181:74-82. PMID: 27823696
9. Sawant RV**, Goyal RK**, **Rajan SS**, Patel HK, Essien EJ, Sangiriy SS. Factors Associated With Intention to Engage In Self-Protective Behavior: The Case of Over-the-Counter Acetaminophen Products. *Res Social Adm Pharm*. 2016 Mar-Apr;12(2):327-35. PMID: 26183416
10. Wills AM†, Pérez A, Wang J, Su X, Morgan J, **Rajan SS**, Leehey MA, Pontone GM, Chou KL, Umeh C, Mari Z, Boyd J. Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1. *JAMA Neurol*. 2016 Mar;73(3):321-328. PMID: 26751506 PMCID: PMC5469290
11. Bowry R†, Parker S, **Rajan SS**, Yamal JM, Wu TC, Richardson L, Noser E, Persse D, Jackson K, Grotta JC. Benefits of Stroke Treatment Using a Mobile Stroke Unit Compared With Standard Management: The BEST-MSU Study Run-In Phase. *Stroke*. 2015 Dec;46(12):3370-3374. PMID: 26508753

12. Highfield L†, **Rajan SS**, Valerio MA, Walton G, Fernandez ME, Bartholomew LK. A non-randomized controlled stepped wedge trial to evaluate the effectiveness of a multi-level mammography intervention in improving appointment adherence in underserved women. *Implement Sci.* 2015 Oct 14;10:143. PMID: 26464110
13. **Rajan SS**‡†, Begley CE, Highfield LD, Kim B. Survival benefits of treatment access among underserved breast cancer patients diagnosed through the Texas Breast and Cervical Cancer Services program. *J Public Health Manag Pract.* 2015 Sep-Oct;21(5):477-486. PMID: 25794245
14. Jadav S**, **Rajan SS**, Abughosh S, Sansgiry SS. The Role of Socioeconomic Status and Health Care Access in Breast Cancer Screening Compliance Among Hispanics. *J Public Health Manag Pract.* 2015 Sep-Oct;21(5):467-476. PMID: 25756197
15. Kadakia A**, **Rajan SS**‡, Abughosh S, Du XL, Johnson ML. CMF-regimen preferred as first-course chemotherapy for older and sicker women with breast cancer: Findings from a SEER-Medicare-based population study. *Am J Clin Oncol.* 2015 Apr;38(2):165-173. PMID: 23608830
16. **Rajan SS**†, Baraniuk S, Parker S, Wu TC, Bowry R, Grotta JC. Implementing A Mobile Stroke Unit Program in the United States: Why, How and How Much? *JAMA Neurol.* 2015 Feb;72(2):229-234. PMID: 25485723
17. Kiebertz K†, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB Jr, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Pérez A, Petrovitch H, **Rajan SS**, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM. Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease: A Randomized Clinical Trial. *JAMA.* 2015 Feb 10;313(6):584-593. PMID: 25668262 PMCID: PMC4349346
18. Bhowmik D*, Aparasu RR, **Rajan SS**, Sherer JT, Ochoa-Perez M, Chen H. Risk of manic switch associated with antidepressant therapy in pediatric bipolar depression. *J Child Adolesc Psychopharmacol.* 2014 Dec;24(10):551-561. PMID: 25470655
19. **Rajan SS**‡, † Begley CE, Kim B. Breast cancer stage at diagnosis among medically underserved women screened through the Texas Breast and Cervical Cancer Services. *Popul Health Manag.* 2014 Aug;17(4):202-210. PMID: 24921895
20. Yu Y**, **Rajan SS**, Essien EJ, Yang M, Abughosh S. The relationship between obesity and prescription of smoking cessation medications. *Popul Health Manag.* 2014 Jun;17(3):172-179. PMID: 24784163
21. Choi S*, **Rajan SS**, Trivedi MV. The Incidence of Tumor Cell Contamination of Peripheral Blood Stem Cells: A Meta-Analysis to Evaluate the Impact of Mobilization Regimens and the Influence on Outcomes in Breast Cancer Patients. *Acta Haematol.* 2014;131(3):133-140. PMID: 24192756
22. Yu Y**, **Rajan SS**, Essien EJ, Chen H, Yang M, Abughosh S. Obesity and Prescription of Smoking Cessation Medications. *J Behav Health.* 2013; 2(4): 291-298.
23. Bhowmik D*, Aparasu RR, **Rajan SS**, Sherer JT, Ochoa-Perez M, Chen H. The utilization of psychopharmacological treatment and medication adherence among Medicaid enrolled children and adolescents with bipolar depression. *J Affect Disord.* 2013 Sep 5;150(2):424-429. PMID: 23747210
24. **Rajan SS**‡, Carpenter WR, Stearns SC, Lyman GH. Short-term Costs Associated with Primary Prophylactic G-CSF Use during Chemotherapy. *Am J Manag Care.* 2013 Feb;19(2):150-159. PMID: 23448112

25. Mehta HB**, **Rajan SS**, Aparasu RR, Johnson ML. Application of the Nonlinear Blinder-Oaxaca Decomposition to Study Racial/Ethnic Disparities in Anti-obesity Medication Use in the United States. *Res Social Adm Pharm.* 2013 Jan-Feb;9(1):13-26. PMID: 22554395
26. Goyal RK**, **Rajan SS**, Essien EJ, Sansgiry SS. Effectiveness of FDA's New Over-the-Counter Acetaminophen Warning Label in Improving Consumer Risk Perception of Liver Damage. *J Clin Pharm Ther.* 2012 Dec;37(6):681-685. PMID: 22958105
27. Abughosh S, Wu IH, **Rajan SS**, Peters RJ, Essien EJ. Waterpipe Smoking Among Students in One US University: Predictors of an Intention to Quit. *J Am Coll Health.* 2012;60(7):528-535. PMID: 23002801
28. Yang M**, **Rajan SS**, Issa AM. Cost Effectiveness of Gene Expression Profiling for Early Stage Breast Cancer: A Decision Analytic Model. *Cancer.* 2012 Oct 15;118(20):5163-5170. PMID: 22359236
29. **Rajan SS**‡, Stearns SC, Lyman GH, Carpenter WR. Effect of Primary Prophylactic G-CSF Use on Systemic Therapy Administration for Elderly Breast Cancer Patients. *Breast Cancer Res Treat.* 2011 Nov;130(1):255-266. Epub 2011 May 17. PMID: 21584667
30. **Rajan SS**‡, Lyman GH, Stearns SC, Carpenter WR. Effect of Primary Prophylactic granulocyte-colony stimulating factors use on Incidence of Neutropenia Hospitalizations for Elderly Early-stage Breast Cancer Patients Receiving Chemotherapy. *Med Care.* 2011 Jul;49(7):649-657. PMID: 21478779
31. **Rajan SS**‡, Lyman GH, Carpenter WR, Stearns SC. Chemotherapy Characteristics are Important Predictors of Primary Prophylactic CSF Administration in Older Patients with Breast Cancer. *Breast Cancer Res Treat.* 2011 Jun;127(2):511-520. Epub 2010 Oct 26. PMID: 20976544
32. **Rajan SS**, Sokal D. A Simpler Tool for Estimation of HIV Incidence from Cross-Sectional, Age-Specific Prevalence Data. *J Epidemiol Community Health.* 2011 Feb;65(2):111-115. Epub 2010 Jun 16. PMID: 20558420
33. **Rajan SS**, Sokal DC. Comparison of Projected and Actual Outcomes of the HIV/AIDS Epidemic in Malawi, 1990-2000. *PLoS One.* 2009 Aug 27;4(8):e6806. PMID: 19710919 PMCID: PMC2728838
34. **Rajan SS**‡, Pink GH, Dow WH. Sociodemographic and Personality Characteristics of Canadian Donors Contributing to International Charity. *Nonprofit and Voluntary Sector Quarterly.* 2009 Jun;38(3):413-440

B.2.2 NON PEER-REVIEWED PUBLICATIONS

1. **Rajan SS**, Yang M, Issa A. Response to reply to cost effectiveness of gene expression profiling for early stage breast cancer: A decision-analytic model. *Cancer.* 2012 Jun 6. Epub ahead of print. PMID: 22674087

B.2.3 WHITE PAPERS

1. Weber ES, **Rajan SS**. Price Transparency in the Context of the American Health Care Market: Theory and Evidence from the Literature. Submitted to **Texas Department of Insurance**. July 2015
2. Revere FL, Begley CE, **Rajan SS**, Karanth S, Ratanatawan A, Abbass I. Texas Medicaid Outcomes Evaluation Study: Key Findings Comparing Medicaid and Commercial Utilization Rates and Trends. Submitted to **Methodist Health Ministries**. October 2014
3. Begley CE, Rajan SS, Kim B. Texas Breast and Cervical Cancer Services Program Outcomes Study. Submitted to Cancer Prevention and Research Institute of Texas. November 2012

B.2.4 PEER-REVIEWED PUBLICATIONS IN PROGRESS

* Student first author ‡ Suja S. Rajan is the Corresponding author

1. Ganduglia Cazaban CM, Weber ES, Nguyen LK, Revere FL, **Rajan SS‡**. Algorithms to identify deliveries using different administrative claims datasets. – **In preparation (Manuscript being drafted, analysis complete; Target Journal – Journal of Public Health Management and Practice).**
2. **Rajan SS‡**, Tilley B, Dahwodwala N, Hauser R, Augustine E, Perez A, Kiebertz K. Costs associated with treatment of early stage Parkinson’s Disease among patients enrolled in the NET-PD clinical trial. – **In preparation (Final analysis ongoing and draft initiated; Target Journal – JAMA Neurology).**
3. Weber ES, **Rajan SS‡**. Price Transparency in the Context of the American Health Care Market: Theory and Evidence from the Literature. – **In preparation (White paper being edited for submission; Target Journal – Health Services Research).**

B.3.1 INVITED PRESENTATIONS

1. Comparative effectiveness of long-acting versus short-acting granulocyte colony-stimulating factors in breast cancer patients. Public Health Grand Round Speaker, University of Virginia School of Medicine, Charlottesville, VA. September 25th, 2017
2. Studies examining clinical outcomes and costs associated with breast cancer management. Veterans Affairs Health Services Research & Development, Center of Excellence, Houston, TX. April 2015

B.3.2 PEER-REVIEWED PRESENTATIONS

1. Rajan SS, Kiebertz K, Dahodwala N, Augustine E, Hauser R, Tilley BC. Predictors of Healthcare Utilization and Costs among Early-Stage Parkinson’s Disease Patients: NET-PD study. Podium Presentation – Boston 2017 Congress, International Health Economics Association, Boston, MA. July, 2017
2. Bhansali A, Fleming ML, Essien EJ, Mehta P, Rajan SS, Sansgiry SS. Effect of patient involvement on intention to initiate breast cancer chemoprevention. Poster Presentation - 22nd Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Boston, MA. May, 2017
3. Nguyen LK, Rajan SS, Weber ES, Ganduglia Cazaban CM. Algorithms to identify deliveries using different administrative claims datasets. American Public Health Association Poster Presentation. Chicago, IL. October, 2015.
4. Highfield LD, Bartholomew LK, Rajan SS, Fernandez M, Valerio M, Walton G, Chambers D, Asgarisabet P. Intervention Mapping for Implementation Intervention Development: A Systematic Approach. Poster Presentation at the AHRQ Research Conference. Crystal City, VA. October, 2015.
5. Virani SS, Akeroyd JA, Ramsey DJ, Chan WJ, Rajan SS, Ballantyne CM, Petersen LA. Comparative Effectiveness of Outpatient Cardiovascular Disease Care Delivery Between Physician and Non-Physician Primary Care Providers: Implications for Care Under the Affordable Care Act. Poster presentation at the American Heart Association Quality of Care and Outcomes Research Council 2015 Scientific Sessions, Baltimore, MD. April, 2015.
This poster received extensive media coverage including press release from the American Heart Association, Health day news, theHeart.org, Cardiology Today, Cardiovascular Business, and Consumer

Reports on Health. Overall, there were 29.5 million viewers/readers of this article in more than 23 media outlets.

6. Virani SS, Akeroyd JM, Ramsey DJ, Chan WJ, Rajan S, Ballantyne CM, Petersen LA. Provider Type and the Quality of Diabetes Care: Implication for the Affordable Care Act (ACA). Poster presentation at the Annual Scientific Session of the American Diabetes Association, Boston, MA. June, 2015.
Also selected for Guided Audio Poster Tour.
7. Rajan SS, Cai Y, Yi M, Tsai C, Du XL. Use of Hematopoietic Growth Factors in Elderly Lung Cancer Patients Receiving Chemotherapy: A SEER-Medicare Based Study. Academy Health Annual Research Meeting Poster Presentation. San Diego, CA. June, 2014.
8. Perez MO, Bhowmik D, Chen H, Aparasu RR, Rajan SS, Sherer JT, Perez MO. Risk of manic switch with antidepressant therapy in pediatric bipolar depression. American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting, Orlando, FL. October, 2013.
9. Rajan SS, Begley CE, Kim B. Evaluation of the Texas breast cancer screening services Program. International Health Economics Association (IHEA) **Podium** Presentation. Sydney, Australia. July, 2013.
10. Begley CE, Rajan SS, Kim B. Texas breast cancer early detection and treatment outcomes study. CPRIT Conference Poster Presentation. Austin, TX. November, 2012.
11. Wu IH, Rajan SS, Peters RJ, Essien EJ, Abughosh S. Waterpipe Smoking among University Students in the United States: Predictors of an Intention to Quit. 17th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Washington DC. May, 2012
12. Bhowmik D, Chen H, Aparasu RR, Rajan SS, Sherer JT, Perez MO. Pharmacotherapy and Associated Outcomes in Pediatric Bipolar Depression. 17th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Washington DC. May, 2012
13. Bhattacharya R, Aparasu RR, Rajan SS, Chen H. Obesity and Risk of Depression/Anxiety in Children and Adolescents: A Medical Expenditure Panel Survey Study. 17th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Washington DC. May, 2012
14. Abughosh S, Yu Y, Yang M, Rajan SS, Essien EJ. Smoking Cessation Medication Use Among Adult Smokers With Various Body Weight Levels – an NHANES Study. 17th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Washington DC. May, 2012
15. Yang M, Yu Y, Rajan SS, Essien EJ, Abughosh S. Smoking Cessation Medication Utilization Pattern Among Adult Smokers With Different Body Weight Levels – a NAMCS Study. 17th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Washington DC. May, 2012
16. Shah A, Chen H, Rajan SS, Johnson ML. Impact of Long Acting Insulin Agents on Health Related Quality of Life (HRQoL), Health Care Expenditures and Utilization. 17th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Washington DC. May, 2012
17. Kadakia A, Rajan SS, Du XL, Johnson ML. Predictors of Methotrexate Containing Chemotherapy in Women Diagnosed With Early Stage Breast Cancer. 17th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Washington DC. May, 2012
18. Rajan SS, Begley CE, Kim B. Texas breast cancer early detection and treatment outcomes study. CPRIT Conference PODIUM Presentation. Austin, TX. November, 2011.

19. Begley CE, Rajan SS, Kim B. Texas breast cancer early detection and treatment outcomes study. CPRIT Conference Poster Presentation. Austin, TX. November, 2011.
20. Rajan SS, Begley CE, Kim B. Predictors of Timely Receipt of Breast Cancer Diagnosis and Treatment among Patients Receiving Their First Mammograms through the Texas Breast and Cervical Cancer Early Detection Program. Academy Health 2011 Annual Research Meeting Poster Presentation. Seattle, WA. June 2011.
21. Begley CE, Rajan SS, Kim B. Trends in Adherence to Texas Breast and Cervical Cancer Early Detection Program Performance Benchmarks: 1991 to 2009. Academy Health 2011 Annual Research Meeting Poster Presentation. Seattle, WA. June 2011.
22. Mehta H, Rajan S, Aparasu R, Johnson M. National trends in anti-obesity medication use from 2002 to 2007. Poster Presentation - 16th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD. May, 2011.
23. Mehta H, Rajan S, Aparasu R, Johnson M. Application of the non-linear Blinder-Oaxaca decomposition to study racial/ethnic disparities in anti-obesity medication use. Poster Presentation - 16th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD. May, 2011.
24. Kadakia A, Mehta H, Rajan S, Abughosh S. Does clinical diagnosis of obesity increase the likelihood of receiving obesity related counseling? A 2005-2008 NAMCS-NHAMCS Analysis. Poster Presentation - 16th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD. May, 2011.
25. Patel J, Rajan S, Aparasu R, Johnson M. Impact of obesity on age-specific prevalence of chronic diseases in the United States. Poster Presentation - 16th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD. May, 2011.
26. Patel J, Rajan S, Aparasu R, Johnson M. Prevalence ratios against odds ratios as effect measures in a cross-sectional study of obesity and its chronic comorbid conditions. Poster Presentation - 16th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD. May, 2011.
27. Patel J, Aparasu R, Rajan S, Johnson M. Factors leading to high health care expenditure among obese individuals in the United States. Poster Presentation - 16th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD. May, 2011.
28. Parikh R, Rajan S, Aparasu R, Johnson M. Effect of ACEI and ARB on health related quality of life in patients with hypertension and diabetes. Poster Presentation - 16th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD. May, 2011.
29. Shah A, Patel J, Rajan S, Abughosh S, Masilamani S. Disparity in obesity management: Under-Treatment among elderly population. Poster Presentation - 16th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD. May, 2011.
30. Karkare S, Rajan S, Chen H, Aparasu R. Antidepressant persistence and associated healthcare expenditure in children with depression. Poster Presentation - 16th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD. May, 2011.
31. Goyal RK, Rajan SS, Essien EJ, Sansgiry S. Effectiveness of FDA's new over-the-counter acetaminophen label warning requirements in improving consumer risk perception of liver damage. Poster Presentation - 16th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD. May, 2011.

32. Parikh R, Shah A, Rajan S, Aparasu R, Johnson M. Quality of care among hypertensive diabetic adults. Poster Presentation - 23rd Annual Meeting & Showcase, Academy of Managed Care Pharmacy, Minneapolis, MN. April, 2011.
33. Rajan S, Lyman G. Economics of Primary Prophylactic G-CSF use in preventing neutropenia and improving chemotherapy in elderly breast cancer patients: are short-term increase in costs necessarily bad? Poster Presentation - 11th Annual Health Services and Outcomes Research Conference, Kelsey Research Foundation, Houston, TX. December, 2010.
34. Patel J, Shah A, Rajan S, Aparasu R, Johnson M. Want to treat chronic diseases? Treat obesity first! Poster Presentation - 11th Annual Health Services and Outcomes Research Conference, Kelsey Research Foundation, Houston, TX. December, 2010.
35. Mehta S, Shah J, Rajan S, Aparasu R, Johnson M. National trends in anti-obesity medication use from 200 to 2007. Poster Presentation - 11th Annual Health Services and Outcomes Research Conference, Kelsey Research Foundation, Houston, TX. December, 2010.
36. Kadakia A, Mehta H, Rajan S, Abughosh S. Diet, Exercise and weight reduction counseling for obese patients during ambulatory care visit in the USA from 2005-2008. Poster Presentation - 11th Annual Health Services and Outcomes Research, Kelsey Research Foundation Conference, Houston, TX. December, 2010.
37. Shah A, Patel J, Rajan S, Masilamani S, Abughosh S. Quality of care among elderly diagnosed with obesity: A 2006-2008 analysis. Poster Presentation - 11th Annual Health Services and Outcomes Research, Kelsey Research Foundation, Houston, TX. December, 2010.
38. Begley CE, Rajan SS, Du X. Breast Cancer Screening and Early Detection in the Texas BCCS Program 1995-2007. CPRIT Innovations in Cancer Prevention and Research Conference Poster Presentation. Austin, TX. November, 2010.
39. Rajan S, Lyman G. Effect of Primary Prophylactic G-CSF Use on Successful Systemic Therapy Administration for Elderly Breast Cancer Patients – Academy Health 2010 Annual Research Meeting Poster Presentation. Boston, MA. June 2010.
40. Rajan S, Lyman G. Effect of primary prophylactic G-CSF use and duration of use on neutropenia hospitalizations for elderly breast cancer patients receiving chemotherapy – ISPOR 15th Annual International Meeting **Podium** Presentation. Atlanta, GA. May 2010.
41. Rajan S, Lyman G. Clinical and socio-demographic determinants of primary prophylactic G-CSF use in elderly breast cancer Medicare beneficiaries receiving chemotherapy – ISPOR 15th Annual International Meeting Poster Presentation. Atlanta, GA. May 2010.
42. Rajan S, Lyman G. Effect of Primary Prophylactic G-CSF Usage on Neutropenia Hospitalizations for Elderly Breast Cancer Patients Receiving Chemotherapy. 10th Annual Health Services and Outcomes Research Conference, Kelsey Research Foundation, Houston, TX. December 2009.
43. Sokal D, Rajan S, Ma YR, Chien PL, Mugo L, Bukusi E. Using Age-Specific Prevalence to Estimate HIV Incidence. Poster TB-244, *Microbicides* 2008 Conference, Feb. 24-28, New Delhi.

C. TEACHING EXPERIENCE

C.1.1 COURSES TAUGHT AT UT SPH

<i>Semester</i>	<i>Course name</i>	<i>Role</i>	<i>Number of students</i>	<i>Student assessed teaching effectiveness (Score is out of 5)</i>
Spring 2017	Advanced Econometrics PHD 3931	Lead instructor 100%	25	4.8
Fall 2016	Advanced Health Services Research Method PHD 3945	Co-instructor 40%	14	5.0 (All Instructors: 4.69)*
Fall 2016	Methods for the Economic Evaluation of Health Programs PH 3915	Co-instructor 20%	26	4.9 (All Instructors: 4.9)*
Spring 2016	Advanced Econometrics PHD 3931	Lead instructor 100%	18	4.9
Fall 2015	Methods for the Economic Evaluation of Health Programs PH 3915	Co-instructor 20%	37	4.4 (All Instructors: 4.7)*
Fall 2015	Advanced Health Economics PHD 3935	Co-instructor 33%	11	5.0 (All Instructors: 5.0)*
Spring 2015	Advanced Econometrics PHD 3931	Lead instructor 100%	8	4.8
Fall 2014	Advanced Health Services Research Method PHD 3945	Co-instructor 20%	3	5.0 (All Instructors: 4.5)*
Spring 2014	Advanced Econometrics PHD 3931	Lead instructor 100%	18	4.7
Fall 2013	Doctoral Seminar – MPACH PHD 3980	Lead instructor 100%	14	4.0
Fall 2013	Advanced Health Economics PHD 3935	Co-instructor 33%	10	4.9 (All Instructors: 4.9)*
Spring 2013	Advanced Econometrics PHD 3931	Lead instructor 100%	15	4.8
Spring 2013	Advanced Health Services Research Method PHD 3945	Co-instructor 20%	20	4.1 (All Instructors: 4.2)*
Spring 2012	Advanced Econometrics PHD 3998	Lead instructor 100%	13	4.2

* Average for all instructors teaching the course

C.1.2 COURSES TAUGHT OUTSIDE UT SPH (BEFORE EMPLOYMENT AT UT SPH)

- Courses taught as the course coordinator/lead instructor - Advanced Statistical Methods; Seminar in Pharmacy Administration; Pharmacy Management II (Dealt with Financial aspects of healthcare management).
- Courses taught as co-instructor/co-coordinator - Pharmacy Management II (Dealt with Financial aspects of healthcare management); Applications of Strategic Management in Healthcare Organization.
- Courses taught as a guest lecturer - Regression Analysis and Methods; Financial Aspects of Healthcare Management; Research Methods in Pharmacy Administration; Pharmacy Management I (Class on Health Policy); Pharmacy Administration and Management II.

C.2.1 STUDENT MENTORING AT UT SPH

Advisor/Dissertation Chair – PhD/Dr.PH:

Zheng (Mily) Wang	PhD-MPACH	2012-2014 (Graduated)
Siddharth Karanth	DrPH-MPACH	2014-2016 (Graduated)
Parisa Asgarisabet	PhD-MPACH	2014-present
Viraj Bhise	PhD-MPACH	2014-present
Hilda Sekabira	PhD-MPACH	2015-present
Vidya Venkataraman	PhD-MPACH	2015-present
Lu Zhang	PhD-MPACH	2015-present
Danmeng Huang	PhD-MPACH	2016-Present (Dissertation Supervisor)
Priyadarsini Dasari	PhD-MPACH	2017-present

Advisor/Thesis Chair – MPH:

Manasi Suryavanshi	MPH-MAPCH	2013-2014 (Thesis Supervisor – Graduated)
Hannah Vardy	MPH-MPACH	2013-2015 (Graduated)
Hilda Sekabira	MPH-MPACH	2013-2015 (Graduated)
Jolyn Taylor	MPH-MPACH	2014-2016 (Graduated)
Lauren Ross	MPH-MPACH	2015-2016 (Moved from HSO to CHP)
Debanshu Roy	MPH-MPACH	2015-2017 (Graduated)
Sukhvir Kaur Sandhu	MPH-MPACH	2015-2016 (Graduated)
Shireen Haq	MPH-MPACH	2015-Present
Jessica Wise	MPH-MPACH	2016-Present
Jaden Kohn	MPH-MPACH	2017-Present (Thesis Supervisor)
Susana Penate	MPH-MPACH	2017-Present
Nicole Avellanet	MPH-MPACH	2017-Present
Clarissa Sanchez	MPH-MPACH	2017-Present
Ellen Wadler	MPH-MPACH	2017-Present

Committee Member – PhD/DrPH

Santosh Gautam	PhD-MPACH	2012-2014 (Changed his topic and his committee – Student Graduated)
Bumyang Kim	PhD-MPACH	2010-2015 (Changed his topic and his committee – Student Graduated)
Tania Waheed	PhD-MPACH	2013-2016 (Graduated)
Junghyun Kim	PhD-MPACH	2013-2016 (Graduated)
Sapna Prasad	PhD-MPACH	2013-2017 (Graduated)
Austin Haag	PhD-MPACH	2014-2017 (Graduated)
Ying Cao	PhD-BIOS	2014-2015 (Graduated)
Jue Wang	PhD-BIOS	2015-2016 (Graduated)
Julio Allo	PhD-MPACH	2015-Present
Hyunsoo Hwang	PhD-BIOS	2016-Present
Jue Zhang	PhD-BIOS	2016-Present

Committee Member – MPH

Christopher Manuel	MS-BIOS	2013-2014 (Graduated)
Bo Zhao	MS-BIOS	2015-present

C.2.2 STUDENT MENTORING OUTSIDE UT SPH (UNIVERSITY OF HOUSTON COLLEGE OF PHARMACY)

Aditi Kadakia	Advisor: MS-Pharmacy Administration	2009-2011 (Graduated)
Mark Kramer	Advisor: PhD-Pharmacy Administration	2010-2012 (Student switched advisor after I moved)
Sneha Mehta	Advisor: MS-Pharmacy Administration	2010-2012 (Student switched advisor after I moved)
Shweta Kakad	Advisor: MS-Pharmacy Administration	2010-2012 (Student switched advisor after I moved)

Archita Bhansali	Committee Member: PhD-Pharmacy Administration	2015-2017 (Graduated)
Smruti Jadav	Committee Member: MS-Pharmacy Administration	2012-2013 (Graduated)
Debajyoti Bhowmik	Committee Member: PhD-Pharmacy Administration	2011-2013 (Graduated)
Ankit Shah	Committee Member: MS-Pharmacy Administration	2010-2011 (Graduated)
Rituparna Bhattacharya	Committee Member: MS-Pharmacy Administration	2010-2011 (Graduated)
Yuping Yu	Committee Member: MS-Pharmacy Administration	2009-2011 (Graduated)
Hemal Mehta	Committee Member: MS-Pharmacy Administration	2009-2010 (Graduated)
Jeetvan Patel	Committee Member: MS-Pharmacy Administration	2009-2010 (Graduated)
Rohan Parikh	Committee Member: MS-Pharmacy Administration	2009-2010 (Graduated)
Swapna Karkare	Committee Member: MS-Pharmacy Administration	2009-2010 (Graduated)
Ravi Goyal	Committee Member: MS-Pharmacy Administration	2009-2010 (Graduated)

D. SERVICES

D.1 SERVICES TO THE UNIVERSITY

- University of Texas – **Director HE/HSR PhD Program** (January 2016-Present)
- University of Texas – **School-wide Curriculum Committee – Member** (January 2016-Present)
- University of Texas – **School-wide Faculty Awards Committee - Member** (2015-2017)
- University of Texas – School wide presentation about the “Availability and Use of Various Claims Datasets”, available through the UT SPH/BCBSTX Payment Systems and Policies Research Program in collaboration with Dr. Cecilia Ganduglia-Cazaban. (September 19th, 2014)
- University of Texas – CHPPR Cancer Research Group - Datasets/Data Analysis Sub-Group – Leader (2013-2015)
- University of Texas – CHPPR Cancer Research Group – Member (2013-2015)
- University of Texas – Applicant evaluation and voting for HE/HSR and HSO student admissions (2012-present)
- University of Texas – **School-wide Faculty Council – Member** (2012-2015)
- University of Texas – **Scholarship Committee – Member** (2012)
- University of Houston – Admissions committee – Member (2010-2012)
- University of Houston – Faculty Merit Review committee – Member (2011)
- University of Houston – Curriculum Review for Graduate Level Statistics sub-committee –Member (2010-2012)
- University of Houston – College of Pharmacy Self-Study Reading committee – Reader (2011)

D.2 REVIEWER FOR PEER-REVIEWED JOURNALS (1-2 articles per journal except Medical Care)

- Medical Care (16 articles reviewed)
- Value in Health
- Journal of Clinical Oncology
- American Journal of Managed Care
- Breast Cancer Research and Treatment
- Head and Neck
- BMC Geriatrics

- Drugs and Aging
- Journal of Managed Care Pharmacy
- Journal of Medical Economics
- American Journal of Preventive Medicine
- Non-profit and Voluntary Sector Quarterly
- Texas Public Health Journal
- Cancer Investigation
- Journal of Public Health Management and Practice
- Movement Disorders
- Stroke

D.3 EXTERNAL SERVICES TO THE PROFESSION

1. Invited for being a reviewer for the “Omnibus Funding Opportunity Announcements (FOAs) PAR-14-007 (R03s) and PAR-13-146 (R21s), NCI Small Grants Program for Cancer Research) and NCI Exploratory/Developmental Research Grant Program”. October 14-15, Washington DC. Declined as this was close to my pregnancy due date but agreed to participate for an invitation in 2016.
2. Invited for being a reviewer for the Omnibus Funding Opportunity Announcement (FOA) PAR-14-007 (R03s), NCI Small Grants Program for Cancer Research. June 11-12, 2015, Washington, DC. Declined due to health reasons (bed rest and treatment during second trimester of pregnancy) but agreed to participate for an invitation in 2016.
3. Abstract Reviewer: IHEA abstracts – 2013; ISPOR abstracts – 2010 and 2011
4. Poster and podium awards judging panel – ISPOR 2011
5. Faculty Advisor: ISPOR-UT SPH student chapter (2015-Present)
6. Free consultations and advice about health economics and statistics/econometrics concepts and study design for colleagues at the Medical Center and outside who are working on unfunded projects or are unable to budget for an economist in their grants. These are usually just one time consultations or on and off assistance to make sure their methods are right. These usually do not result in any research products like publications.

D.4 COMMUNITY SERVICES

Volunteer teacher at the Literacy Advance Houston

D.5 MEMBERSHIPS

2009-2010 American Association for College of Pharmacy
 2009-present International Society for Pharmacoeconomics and Outcomes Research
 2009-present Academy Health
 2012-present International Health Economics Association

E. TECHNICAL AND STATISTICAL SKILLS

- Excellent working knowledge of Statistical software – STATA, R, SAS, Treeage, JMP, SPSS, FORTRAN, SUDAAN, SPECTRUM (Including AIM, DemProj and EpiModel)

- Excellent working knowledge of other software – MS Office (Including Macros programming in Excel), MATLAB, EndNote, ProCite
- Good working knowledge of Atlas ti, Crystal Ball, @RISK
- Good understanding of the AIDS Risk Reduction Model In-depth knowledge of principles underlying Statistical Design of Experiments
- Excellent data management skills due to experience with claims and other population based data including Texas Cancer Registry, Medicare, Medicaid, Surveillance Epidemiology and End Results (SEER) linked to Medicare claims, Consumer Assessment of Healthcare Providers and Systems linked to Medicare claims, and National Survey of Giving, Volunteering, and Participating.
- Strong fundamentals through extensive coursework in Microeconometrics, Biostatistics, Statistical Modeling using longitudinal data, Duration Modeling (Survival Analysis), Cost-effectiveness Analysis, Sample Survey Methods, Demographic Techniques, Life Table Analysis, Probability Theory, Monte Carlo Simulation, Markov Modeling